MACK Merrimack Pharmaceuticals Inc.

4.11
-0.07  -2%
Previous Close 4.18
Open 4.15
Price To Book 1.37
Market Cap 54,921,729
Shares 13,362,951
Volume 68,288
Short Ratio
Av. Daily Volume 61,301
Stock charts supplied by TradingView

NewsSee all news

  1. JFL Capital Ends Campaign at Merrimack

    LAKEWAY, Texas, Sept. 24, 2019 /PRNewswire/ -- JFL Capital Management, LLC (together with its affiliates, "JFL Capital"), the largest stockholder of Merrimack Pharmaceuticals, Inc. ("Merrimack" or the

  2. Merrimack Pharmaceuticals Announces Changes to Board of Directors

    Company Enters into Cooperation Agreement with Newtyn Management and Western Standard Independent Directors Noah Levy of Newtyn and Eric Andersen of Western Standard to Be Added to Merrimack Board, Effective

  3. Merrimack Pharmaceuticals Announces Per Share Amount for Previously Declared Special Dividend

    Dividend Amount is $1.496675 per Outstanding Share of Merrimack Common Stock and Will be Paid Today, as Previously Announced Company Provides Update on NOL Carryforwards; No Impairment as of July 24, 2019 Merrimack

  4. Merrimack Pharmaceuticals Issues Letter to Shareholders

    Company's Board has Taken Crucial Actions to Maximize Shareholder Value and Preserve More than $500 Million in Potential Future Milestone Payments Merrimack's Current Plan Follows Comprehensive Strategic Review

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial termination announced November 7, 2018.
MM-121 (SHERBOC)
HER2 negative metastatic breast cancer
Phase 2 data released June 25, 2018 - endpoints not met.
MM-141 - CARRIE
Cancer - front line pancreatic cancer
Phase 2 trial discontinued December 21, 2016 due to poor efficacy.
MM-302 HERMIONE
Cancer - HER2-positive locally advanced or metastatic breast cancer
Approved October 22, 2015.
ONIVYDE
Cancer - second line pancreatic
Phase 2 trial discontinued due to futility - noted October 19, 2018.
MM-121 SHERLOC
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
Acquired by Ipsen
ONIVYDE
Cancer - HER2-negative gastric cancer
Acquired by Ipsen
ONIVYDE
Cancer - front line pancreatic
Announced April 4, 2019 discontinuation of development.
MM-310
Solid tumors
Poster at ASCO June 2018.
MM-121
Solid tumors

Latest News

  1. JFL Capital Ends Campaign at Merrimack

    LAKEWAY, Texas, Sept. 24, 2019 /PRNewswire/ -- JFL Capital Management, LLC (together with its affiliates, "JFL Capital"), the largest stockholder of Merrimack Pharmaceuticals, Inc. ("Merrimack" or the

  2. Merrimack Pharmaceuticals Announces Changes to Board of Directors

    Company Enters into Cooperation Agreement with Newtyn Management and Western Standard Independent Directors Noah Levy of Newtyn and Eric Andersen of Western Standard to Be Added to Merrimack Board, Effective

  3. Merrimack Pharmaceuticals Announces Per Share Amount for Previously Declared Special Dividend

    Dividend Amount is $1.496675 per Outstanding Share of Merrimack Common Stock and Will be Paid Today, as Previously Announced Company Provides Update on NOL Carryforwards; No Impairment as of July 24, 2019 Merrimack

  4. Merrimack Pharmaceuticals Issues Letter to Shareholders

    Company's Board has Taken Crucial Actions to Maximize Shareholder Value and Preserve More than $500 Million in Potential Future Milestone Payments Merrimack's Current Plan Follows Comprehensive Strategic Review